ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grundy, R G
Right arrow Articles by Chessells, J M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grundy, R G
Right arrow Articles by Chessells, J M
Arch Dis Child 1997;76:190-196 ( March )

Survival and endocrine outome after testicular relapse in acute lymphoblastic leukaemia

R G Grundy,a A D Leiper,c R Stanhope,b J M Chessellsa

a Department of Haematology and Oncology, Institute of Child Health, London, b Department of Endocrinology, Institute of Child Health, London, c Department of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Trust, London

Correspondence to: Dr R G Grundy, Haematology and Oncology, Institute of Child Health, Guilford Street, London WC1N 1EH.

Accepted 4 November 1996

Survival and endocrine status in a cohort of boys with acute lymphoblastic leukaemia (ALL) who started treatment between 1972 and 1987 and subsequently developed a testicular relapse were analysed. During this period there was a significant improvement in the overall event free survival for boys, but no significant decrease in the testicular relapse rate. Thirty three boys had an apparently isolated testicular relapse, whereas 21 boys had a combined relapse. The event free survival for boys with an isolated testicular relapse was 59% at six years (95% confidence interval (CI) 42 to 74%). The event free survival for the 16 patients with a combined relapse who received a second course of treatment was 32% (95% CI 17 to 60%). Those patients receiving adequate second line treatment for an isolated testicular relapse whose first remission was longer than or equal to two years had an event free survival of 82% (95% CI 63 to 93%) at six years. No boy relapsing within two years from diagnosis has survived. Endocrine late effects are significant, with 82% of the boys requiring hormonal treatment at some stage for induction of puberty or continuing pubertal maturation, or both. It is concluded that, despite the increasing intensity of initial treatment for ALL, isolated testicular relapse is treatable by conventional means in most patients. Careful endocrine follow up of these patients is essential as most will require hormone replacement treatment.


Key messages

  • Testicular relapse remains an important cause of the failure to cure boys with ALL
  • Isolated testicular relapse after treatment carries an 82% six year survival with adequate retrieval treatment
  • Patients developing a testicular relapse during treatment fare badly
  • Endocrine sequelae in this group of patients are significant, but treatable; long term follow up is essential



Keywords: acute lymphoblastic leukaemia; testicular relapse; late effects.


© 1997 by Archives of Disease in Childhood



This article has been cited by other articles:


Home page
BloodHome page
A. von Stackelberg, R. Hartmann, C. Buhrer, R. Fengler, G. Janka-Schaub, A. Reiter, G. Mann, K. Schmiegelow, R. Ratei, T. Klingebiel, et al.
High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia
Blood, March 1, 2008; 111(5): 2573 - 2580.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1997 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health